Lyell Immunopharma, Inc. Quarterly Debt-to-equity in % from Q1 2022 to Q2 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Lyell Immunopharma, Inc. quarterly Debt-to-equity history and growth rate from Q1 2022 to Q2 2024.
Lyell Immunopharma, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 14.7 %, a 2.29% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q2 2024	14.7	+0.33	+2.29%	Jun 30, 2024
Q1 2024	14.2	-1.3	-8.4%	Mar 31, 2024
Q4 2023	13.5	-4.32	-24.3%	Dec 31, 2023
Q3 2023	13	-6.98	-34.9%	Sep 30, 2023
Q2 2023	14.4	-6.18	-30%	Jun 30, 2023
Q1 2023	15.5	-5.68	-26.8%	Mar 31, 2023
Q4 2022	17.8			Dec 31, 2022
Q3 2022	20			Sep 30, 2022
Q2 2022	20.6			Jun 30, 2022
Q1 2022	21.2			Mar 31, 2022

* An asterisk sign (*) next to the value indicates that the value is likely invalid.